Business Context and Reporting Period
This Form 8-K filing by Design Therapeutics, Inc. (DSGN) reports a corporate governance event dated August 2, 2021. The registrant is a Delaware corporation with principal executive offices in Carlsbad, California, and its common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the departure of Justin Thacker, who notified the Company of his resignation as VP, Finance and principal accounting officer, effective August 13, 2021. Concurrently, Dawn Giangiulio, the Company's Controller, was appointed as the interim principal accounting officer effective August 13, 2021.
Management Commentary and Risks
Management notes that Ms. Giangiulio joined the Company in April 2020 and brings prior experience as Senior Manager R&D Finance at Teva Pharmaceutical Industries Ltd. and Senior Accounting Manager at Auspex Pharmaceuticals, Inc. She is a licensed Certified Public Accountant. The filing states there are no arrangements or understandings between Ms. Giangiulio and other persons regarding her appointment, nor are there family relationships with directors or executive officers requiring disclosure.
Investor Verification Checklist
- Confirm the effective date of the leadership transition (August 13, 2021).
- Verify the interim status of the new principal accounting officer.
- Review subsequent filings for the appointment of a permanent principal accounting officer.
- Check for any related party transactions involving the departing or incoming officers.